Gregory A Jicha1. 1. University of Kentucky College of Medicine, Sanders-Brown Center on Aging, Alzheimer's Disease Center, Department of Neurology, 800 South Limestone Street, Lexington, KY 40536-0230, USA. gajich2@email.uky.edu
Abstract
BACKGROUND: Passive immunization strategies are under investigation as potential disease-modifying therapies for Alzheimer's disease (AD). Current approaches, based on data demonstrating behavioral improvement and reduced pathology in transgenic animal models, have focused exclusively on immune targeting of beta-amyloid. OBJECTIVE: To examine immunization strategies for AD. METHODS: A review of relevant publications. RESULTS/ CONCLUSIONS: Preliminary results from three Phase II trials suggest both the promise and the need to exercise caution with this method of immunotherapy. The strategies used were distinct, using monoclonal N-terminal, central epitope, and polyclonal antibodies to maximize the efficacy and safety of each approach. The tested compounds are moving into Phase III trials for mild to moderate AD. We await the discoveries that from these studies that may yield the first disease-modifying therapy for AD.
BACKGROUND: Passive immunization strategies are under investigation as potential disease-modifying therapies for Alzheimer's disease (AD). Current approaches, based on data demonstrating behavioral improvement and reduced pathology in transgenic animal models, have focused exclusively on immune targeting of beta-amyloid. OBJECTIVE: To examine immunization strategies for AD. METHODS: A review of relevant publications. RESULTS/ CONCLUSIONS: Preliminary results from three Phase II trials suggest both the promise and the need to exercise caution with this method of immunotherapy. The strategies used were distinct, using monoclonal N-terminal, central epitope, and polyclonal antibodies to maximize the efficacy and safety of each approach. The tested compounds are moving into Phase III trials for mild to moderate AD. We await the discoveries that from these studies that may yield the first disease-modifying therapy for AD.
Authors: R Lyle Patton; Walter M Kalback; Chera L Esh; Tyler A Kokjohn; Gregory D Van Vickle; Dean C Luehrs; Yu-Min Kuo; John Lopez; Daniel Brune; Isidro Ferrer; Eliezer Masliah; Amanda J Newel; Thomas G Beach; Eduardo M Castaño; Alex E Roher Journal: Am J Pathol Date: 2006-09 Impact factor: 4.307
Authors: Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos Journal: J Neurosci Date: 2005-01-19 Impact factor: 6.167
Authors: Julianne A Lombardo; Edward A Stern; Megan E McLellan; Stephen T Kajdasz; Gregory A Hickey; Brian J Bacskai; Bradley T Hyman Journal: J Neurosci Date: 2003-11-26 Impact factor: 6.167
Authors: Jason Pitt; William Roth; Pascale Lacor; Amos B Smith; Matthew Blankenship; Pauline Velasco; Fernanda De Felice; Paul Breslin; William L Klein Journal: Toxicol Appl Pharmacol Date: 2009-07-23 Impact factor: 4.219
Authors: Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent Journal: Prog Neurobiol Date: 2019-10-08 Impact factor: 11.685
Authors: Rajesh S Omtri; Michael W Davidson; Balasubramaniam Arumugam; Joseph F Poduslo; Karunya K Kandimalla Journal: Mol Pharm Date: 2012-06-01 Impact factor: 4.939
Authors: Rob J A Nabuurs; Kim S Rutgers; Mick M Welling; Athanasios Metaxas; Maaike E de Backer; Maarten Rotman; Brian J Bacskai; Mark A van Buchem; Silvère M van der Maarel; Louise van der Weerd Journal: PLoS One Date: 2012-06-04 Impact factor: 3.240